These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 6156213

  • 1. Specificity of adoptive chemoimmunotherapy of established syngeneic tumors.
    Cheever MA, Greenberg PD, Fefer A.
    J Immunol; 1980 Aug; 125(2):711-4. PubMed ID: 6156213
    [Abstract] [Full Text] [Related]

  • 2. Therapy of leukemia by nonimmune syngeneic spleen cells.
    Cheever MA, Greenberg PD, Fefer A.
    J Immunol; 1980 May; 124(5):2137-42. PubMed ID: 7365249
    [Abstract] [Full Text] [Related]

  • 3. Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirement for T cells.
    Berenson JR, Einstein AB, Fefer A.
    J Immunol; 1975 Jul; 115(1):234-8. PubMed ID: 1080165
    [Abstract] [Full Text] [Related]

  • 4. Adoptive therapy of established syngeneic leukemia by cells primarily sensitized in vitro.
    Cheever MA, Greenberg PD, Fefer A.
    Cancer Res; 1981 Jul; 41(7):2658-63. PubMed ID: 7018668
    [Abstract] [Full Text] [Related]

  • 5. Generation of long-term T-lymphoid cell lines with specific cytotoxic reactivity for a syngeneic murine lymphoma.
    Eberlein TJ, Rosenstein M, Spiess PJ, Rosenberg SA.
    J Natl Cancer Inst; 1982 Jul; 69(1):109-16. PubMed ID: 6980314
    [Abstract] [Full Text] [Related]

  • 6. Cell-mediated immunity to Friend virus-induced leukemia. III. Characteristics of secondary cell-mediated cytotoxic response.
    Ting CC, Kirchner H, Rodrigues D, Park JY, Herberman RB.
    J Immunol; 1976 Jan; 116(1):244-52. PubMed ID: 54388
    [Abstract] [Full Text] [Related]

  • 7. Suppression of secondary cellular immunity to a tumor allograft by cyclophosphamide and 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Einstein AB, Fass L, Fefer A.
    Cancer Res; 1975 Mar; 35(3):492-6. PubMed ID: 1078784
    [Abstract] [Full Text] [Related]

  • 8. Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ cells: cytolytic T cells can mediate eradication of disseminated leukemia.
    Greenberg PD.
    J Immunol; 1986 Mar 01; 136(5):1917-22. PubMed ID: 3485134
    [Abstract] [Full Text] [Related]

  • 9. Generation of lytic and proliferative lymphoid clones to syngeneic tumor: in vitro and in vivo studies.
    Rosenstein M, Rosenberg SA.
    J Natl Cancer Inst; 1984 May 01; 72(5):1161-5. PubMed ID: 6609266
    [Abstract] [Full Text] [Related]

  • 10. Chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro: effect of culture duration on therapeutic efficacy.
    Cheever MA, Greenberg PD, Fefer A.
    J Natl Cancer Inst; 1981 Jul 01; 67(1):169-73. PubMed ID: 6942187
    [Abstract] [Full Text] [Related]

  • 11. Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors.
    Mokyr MB, Hengst JC, Dray S.
    Cancer Res; 1982 Mar 01; 42(3):974-9. PubMed ID: 6977410
    [Abstract] [Full Text] [Related]

  • 12. Donor T cells can be induced to grow and survive long term in vivo without previous host immunosuppression.
    Chen W, Cheever MA.
    J Immunol; 1994 May 15; 152(10):4767-74. PubMed ID: 8176202
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Adoptively transferred ex vivo activated memory T cells with cyclophosphamide: effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
    Gold JE, Zachary DT, Osband ME.
    Clin Immunol Immunopathol; 1994 Oct 15; 73(1):115-22. PubMed ID: 7923908
    [Abstract] [Full Text] [Related]

  • 15. Treatment of disseminated leukemia with cyclophosphamide and immune cells: tumor immunity reflects long-term persistence of tumor-specific donor T cells.
    Greenberg PD, Cheever MA.
    J Immunol; 1984 Dec 15; 133(6):3401-7. PubMed ID: 6149246
    [Abstract] [Full Text] [Related]

  • 16. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J, Saffold S, Cao X, Krauss J, Chen W.
    J Immunol; 1998 Nov 15; 161(10):5516-24. PubMed ID: 9820528
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cell-mediated immunity to Friend virus-induced leukemia. II. Characteristics of primary cell-mediated cytotoxic response.
    Ting CC, Rodgigues D, Bushar GS, Herberman RB.
    J Immunol; 1976 Jan 15; 116(1):236-43. PubMed ID: 54387
    [Abstract] [Full Text] [Related]

  • 19. Cell-mediated immunity to friend virus-induced leukemia. IV. In vitro generation of primary and secondary cell-mediated cytotoxic responses.
    Ting CC, Bonnard GD.
    J Immunol; 1976 May 15; 116(5):1419-25. PubMed ID: 58034
    [Abstract] [Full Text] [Related]

  • 20. Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated leukemia, and provide specific immunologic memory.
    Klarnet JP, Matis LA, Kern DE, Mizuno MT, Peace DJ, Thompson JA, Greenberg PD, Cheever MA.
    J Immunol; 1987 Jun 01; 138(11):4012-7. PubMed ID: 3108381
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.